1
|
Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, Chuang C, Hartman J, Hwee DT, St. Jean D, Malinowski J, DeBenedetto M, Moebius D, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. J Med Chem 2024; 67:7825-7835. [PMID: 38729623 PMCID: PMC11129190 DOI: 10.1021/acs.jmedchem.3c02413] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 03/11/2024] [Accepted: 04/17/2024] [Indexed: 05/12/2024]
Abstract
Cardiac myosin activation has been shown to be a viable approach for the treatment of heart failure with reduced ejection fraction. Here, we report the discovery of nelutroctiv (CK-136), a selective cardiac troponin activator intended for patients with cardiovascular conditions where cardiac contractility is reduced. Discovery of nelutroctiv began with a high-throughput screen that identified compound 1R, a muscle selective cardiac sarcomere activator devoid of phosphodiesterase-3 activity. Optimization of druglike properties for 1R led to the replacement of the sulfonamide and aniline substituents which resulted in improved pharmacokinetic (PK) profiles and a reduced potential for human drug-drug interactions. In vivo echocardiography assessment of the optimized leads showed concentration dependent increases in fractional shortening and an improved pharmacodynamic window compared to myosin activator CK-138. Overall, nelutroctiv was found to possess the desired selectivity, a favorable pharmacodynamic window relative to myosin activators, and a preclinical PK profile to support clinical development.
Collapse
Affiliation(s)
- Antonio Romero
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Luke Ashcraft
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Aroop Chandra
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Vincent DiMassa
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Peadar Cremin
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Scott E. Collibee
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Chihyuan Chuang
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - James Hartman
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Darren T. Hwee
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - David St. Jean
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Justin Malinowski
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Mikkel DeBenedetto
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - David Moebius
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Joshua Payette
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Richard Vargas
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - John Yeoman
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Alykhan Motani
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Jeffrey Reagan
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Fady I. Malik
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| | - Bradley P. Morgan
- Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States
| |
Collapse
|
2
|
Sirenko VV, Simonyan AH, Dobrzhanskaya AV, Shelud'ko NS, Borovikov YS. 40-kDa protein from thin filaments of the mussel Crenomytilus grayanus changes the conformation of F-actin during the ATPase cycle. BIOCHEMISTRY. BIOKHIMIIA 2013; 78:273-81. [PMID: 23586721 DOI: 10.1134/s0006297913030097] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Polarized fluorimetry was used to study in ghost muscle fibers the influence of a 40-kDa protein from the thin filaments of the mussel Crenomytilus grayanus on conformational changes of F-actin modified by the fluorescent probes 1,5-IAEDANS and FITC-phalloidin during myosin subfragment (S1) binding in the absence of nucleotides and in the presence of MgADP or MgATP. The fluorescence probes were rigidly bound with actin, which made the absorption and emission dipoles of the probes sensitive to changes in the orientation and mobility of both actin monomer and its subdomain-1 in thin filaments of the muscle fiber. On modeling different intermediate states of actomyosin, the orientation and mobility of oscillators of the dyes were changed discretely, which suggests multistep changes in the actin conformation during the cycle of ATP hydrolysis. The 40-kDa protein influenced the orientation and mobility of the fluorescent probes markedly, suppressing changes in their orientation and mobility in the absence of nucleotides and in the presence of MgADP, but enhancing these changes in the presence of MgATP. The calponin-like 40-kDa protein is supposed to prevent formation of the strong binding state of actomyosin in the absence of nucleotides and in the presence of MgADP but to activate formation of this state in the presence of MgATP.
Collapse
Affiliation(s)
- V V Sirenko
- Institute of Cytology, Russian Academy of Sciences, Tikhoretsky pr. 4, St. Petersburg, Russia
| | | | | | | | | |
Collapse
|